The First Crispr Treatment Is Making Its Way to Patients
The first CRISPR-based treatment, Casgevy, has been approved for sickle cell disease and beta thalassemia, marking a significant advance in gene-editing therapies.
Gene Therapies Could Transform Treatment of Rare Blood Disorders - News Center
Gene therapy shows promising results in treating rare genetic blood disorders like beta thalassemia and sickle cell disease.
Maimonides' holiday party brings comfort and cheer to pediatric patients * Brooklyn Paper
Maimonides Medical Center's holiday party enables pediatric patients to experience joy and normalcy, emphasizing the importance of mental well-being during treatment.
Vertex's CRISPR Gene Therapy Lands Another FDA Nod in a Rare Blood Disease
Vertex Pharmaceuticals and CRISPR Therapeutics' gene therapy, Casgevy, has received FDA approval as a treatment for beta thalassemia.
The therapy provides a one-time treatment option for transfusion-dependent beta thalassemia patients age 12 and older.
The First Crispr Treatment Is Making Its Way to Patients
The first CRISPR-based treatment, Casgevy, has been approved for sickle cell disease and beta thalassemia, marking a significant advance in gene-editing therapies.
Gene Therapies Could Transform Treatment of Rare Blood Disorders - News Center
Gene therapy shows promising results in treating rare genetic blood disorders like beta thalassemia and sickle cell disease.
Maimonides' holiday party brings comfort and cheer to pediatric patients * Brooklyn Paper
Maimonides Medical Center's holiday party enables pediatric patients to experience joy and normalcy, emphasizing the importance of mental well-being during treatment.
Vertex's CRISPR Gene Therapy Lands Another FDA Nod in a Rare Blood Disease
Vertex Pharmaceuticals and CRISPR Therapeutics' gene therapy, Casgevy, has received FDA approval as a treatment for beta thalassemia.
The therapy provides a one-time treatment option for transfusion-dependent beta thalassemia patients age 12 and older.